Are you staying ahead of the curve in CRISPR Technology?

IQPC North America is proud to present CRISPR, A New Era in Gene Editing. We recognize that there are many ground breaking technologies, techniques, and researches occurring that are driving advancements in 2016 and beyond. The CRISPR event takes a comprehensive approach to understand the latest advances in gene editing to enhance drug delivery and develop clinical therapies. The industry’s sharpest minds will speak from their personal experiences and extensive expertise by means of case studies and in-depth workshops to improve CRISPR target efficiency and specificity and look toward the ultimate goal of personalizing medicine.

Download Agenda

Did you know this event is co-located with:

Featured Speakers

View All Speakers

Please see some key highlights that will be addressed in 2016 below:

Examine High-Throughput Functional Genomics using CRISPR–Cas9

A Look Toward The Standardization of CRISPR and Gene Editing Tools

Examine High-Throughput Functional Genomics using CRISPR–Cas9

Next Generation Technology: Easi-CRISPR

Minimizing and Monitoring Off Target Effects in Pre-Clinical Models

Did You Know?


A May 2015 report estimated the genome editing industry to be worth $3.5 billion by 2019.

- According to a new market research report "Genome Editing / Genome Engineering Market by Application (Cell Line Engineering, Animal & Plant Genetic Engineering), Technology (CRISPR, Antisense, TALEN, Zinc Finger Nuclease), & End User (Biotechnology & Pharmaceutical, CRO) - Global Forecast to 2019", published by MarketsandMarkets, the global Genome Editing Market is expected to reach $3,514.08 Million by 2019 from$1,845.25 Million in 2014, growing at a CAGR of 13.75%.


Davies pointed to data from the Tufts Center for the Study of Drug Development (Tufts, 2010) showing that 100 percent of surveyed companies are using a discovery strategy that involves a genetic or genomic approach


More than 80 percent of companies have established strategic partnerships related to personalized medicine, and half have collected DNA samples from clinical trial participants.


According to Davies, the pharmaceutical industry invested an estimated $125 billion in research and development across the industry (Hewitt et al., 2011).


While it’s still early days, one analyst tells Chemistry World the technology could be transformative for companies. ‘The fact a single deal was valued at a potential $2.6 billion tells you something about the overall size the technology could reach,’ says Anette Breindl, senior science editor at Thomson Reuters BioWorld.

See what others are saying about this year’s Pharma IQ events:

Media Partners